The Pharmacogenetics of Antiplatelet Agents: Towards Personalized Therapy?

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2011 Aug 10

PMID 21826075

Citations 13

Authors

Tariq Ahmad

Deepak Voora

Richard C Becker

Affiliations

Soon will be listed here.

Abstract

Considerable variability exists in how individual patients respond to oral antiplatelet therapy, specifically to aspirin and to P2Y(12)-receptor inhibitors such as clopidogrel. This variability translates to differences in clinical outcomes and might in part be as a result of common variation within genes that are involved in the absorption, metabolic activation, and biological activity of these medications. The field of pharmacogenetics has yielded several genetic loci that predict variation in patient response to antiplatelet therapies. The most robust data indicate an association between loss-of-function alleles of the CYP2C19 gene and adverse outcomes among high-risk patients treated with clopidogrel. However, several fundamental questions surrounding the information gained from genotyping and the efficacy of modifying therapy on the basis of testing remain unanswered. Routine genetic testing for platelet responsiveness cannot, therefore, be recommended for clinical decision-making. Ongoing and future clinical trials might provide evidence to support a change in practice towards pharmacogenetic-based selection of antiplatelet therapy.

Citing Articles

Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.

Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A J Clin Med. 2023; 12(5).

PMID: 36902588 PMC: 10003116. DOI: 10.3390/jcm12051799.

Personalizing treatments for patients based on cardiovascular phenotyping.

Leopold J Expert Rev Precis Med Drug Dev. 2023; 7(1):4-16.

PMID: 36778892 PMC: 9913616. DOI: 10.1080/23808993.2022.2028548.

Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Babayeva M, Azzi B, Loewy Z Methods Mol Biol. 2022; 2547:201-240.

PMID: 36068466 DOI: 10.1007/978-1-0716-2573-6_9.

Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention.

Islam M, Nova T, Momenuzzaman N, Rabbi S, Jahan I, Binder T SAGE Open Med. 2021; 9:20503121211042209.

PMID: 34471538 PMC: 8404630. DOI: 10.1177/20503121211042209.

The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study.

Seecheran N, Boodhai B, Maharaj A, Ramdeen A, Debideen N, Ochalal V Cardiol Ther. 2020; 9(2):493-503.

PMID: 32766961 PMC: 7584691. DOI: 10.1007/s40119-020-00195-2.

References

Lev E, Patel R, Guthikonda S, Lopez D, Bray P, Kleiman N . Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2006; 119(3):355-60. DOI: 10.1016/j.thromres.2006.02.006. View

Clarke T, Waskell L . The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2002; 31(1):53-9. DOI: 10.1124/dmd.31.1.53. View

Dandara C, Masimirembwa C, Magimba A, Sayi J, Kaaya S, Sommers D . Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001; 57(1):11-7. DOI: 10.1007/s002280100282. View

Douketis J, Berger P, Dunn A, Jaffer A, Spyropoulos A, Becker R . The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):299S-339S. DOI: 10.1378/chest.08-0675. View

Gurbel P, Bliden K, DiChiara J, Newcomer J, Weng W, Neerchal N . Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007; 115(25):3156-64. DOI: 10.1161/CIRCULATIONAHA.106.675587. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Faraday N, Becker D, Becker L . Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics. 2007; 8(10):1413-25. DOI: 10.2217/14622416.8.10.1413. View

Gum P, Kottke-Marchant K, Poggio E, Gurm H, Welsh P, Brooks L . Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88(3):230-5. DOI: 10.1016/s0002-9149(01)01631-9. View

Tantry U, Mahla E, Gurbel P . Aspirin resistance. Prog Cardiovasc Dis. 2009; 52(2):141-52. DOI: 10.1016/j.pcad.2009.05.001. View

10.

Papafili A, Hill M, Brull D, McAnulty R, Marshall R, Humphries S . Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002; 22(10):1631-6. DOI: 10.1161/01.atv.0000030340.80207.c5. View

11.

Gurbel P, Bliden K, Antonino M, Stephens G, Gretler D, Jurek M . The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2009; 8(1):43-53. DOI: 10.1111/j.1538-7836.2009.03648.x. View

12.

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E . Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005; 116(6):491-7. DOI: 10.1016/j.thromres.2005.03.001. View

13.

Cuisset T, Frere C, Quilici J, Morange P, Saut N, Lambert M . Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res. 2007; 120(6):893-9. DOI: 10.1016/j.thromres.2007.01.012. View

14.

von Beckerath N, Beckerath O, Koch W, Eichinger M, Schomig A, Kastrati A . P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis. 2005; 16(3):199-204. DOI: 10.1097/01.mbc.0000164429.21040.0a. View

15.

Owen A, Goldring C, Morgan P, Chadwick D, Park B, Pirmohamed M . Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol. 2005; 59(3):365-70. PMC: 1884787. DOI: 10.1111/j.1365-2125.2005.02229.x. View

16.

Williams M, Weiss E, Sabatine M, Simon D, Bahou W, Becker L . Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol. 2010; 30(12):2372-84. PMC: 4118751. DOI: 10.1161/ATVBAHA.110.218131. View

17.

Gurbel P, Bliden K, Butler K, Antonino M, Wei C, Teng R . Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010; 121(10):1188-99. DOI: 10.1161/CIRCULATIONAHA.109.919456. View

18.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

19.

Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R . Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J. 2009; 157(5):889-93. DOI: 10.1016/j.ahj.2009.02.013. View

20.

Myrand S, Sekiguchi K, Man M, Lin X, Tzeng R, Teng C . Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008; 84(3):347-61. DOI: 10.1038/sj.clpt.6100482. View